Synopsis
Due to major advances in understanding the biology and pathogenesis of the disease, the management of multiple myeloma is changing rapidly. New diagnostic and prognostic criteria have been introduced, and treatment options are multiplying with high-dose chemotherapy regimens, stem cell transplants, and the development of novel agents and immune-based strategies that target tumor cells directly. This book is aimed at the practitioner who is looking to put these advances into clinical context. It will serve as an up-to-date resource for treatment of myeloma and related disorders. Chapters are written by international authorities and contain color photos, diagrams, and algorithms outlining preferred treatment strategies. Relevant scientific information is integrated throughout, but the focus here is on providing practical therapeutic guidance for oncologists and hematologists caring for myeloma patients. The book covers all myeloma subtypes and related disorders, including amyloidosis, Waldenstrom macroglobulinemia, plasmacytoma, MGUS, and POEMS syndrome.
About the Authors
Dr. S. Vincent Rajkumar is Professor of Medicine at Mayo Clinic College of Medicine and Chair of the Mayo Clinic Myeloma, Amyloidosis, and Dysproteinemia Group. He has authored more than 250 papers and book chapters, primarily in the field of myeloma and related plasma cell disorders. He has led several clinical trials investigating the role of new agents in myeloma. Dr Rajkumar is a member of the American Society of Clinical Oncology Cancer Education Committee as well as the Scientific Advisory Board of the International Myeloma Foundation. Dr. Rajkumar is an associate editor of the Mayo Clinic Proceedings and is on the editorial boards of American Journal of Oncology Review and Leukemia Research.
Dr Robert A. Kyle is Professor of Medicine and Laboratory Medicine at Mayo Clinic in Rochester, Minnesota. He served as the William H. Donner Professor of Medicine and Laboratory Medicine and was Section Head and Chairman of the Division of Hematology. Dr. Kyle is one of the most respected authorities in the field of multiple myeloma and related disorders and has authored more than 750 papers and book chapters, primarily in the field of myeloma and related plasma cell disorders. He has led several major clinical trials and epidemiologic studies in the field. Dr Kyle is currently Chairman of the Scientific Advisory Board of the International Myeloma Foundation, Chairman of the Scientific Advisory Committee of the International Waldenström's Macroglobulinemia Foundation, and President of the International Society of Amyloidosis. During his career, Dr. Kyle has been recognized as the first recipient of the Robert A. Kyle Award for the Waldenstrom's Macroglobulinemia Foundation, first recipient of the Robert A. Kyle Lifetime Achievement Award from the International Myeloma Foundation, Mayo Clinic's Henry S. Plummer Distinguished Internist Award, Mayo Clinic's Distinguished Clinician Award, and the Mayo Clinic's Distinguished Alumni Award. He was also recipient of the 2007 David Karnofsky Award and Lecture at ASCO.
"About this title" may belong to another edition of this title.
